ESMO 2024
Stay up-to-date with the latest coverage of the ESMO 2024 Congress.
In the final segment of our roundtable series, the panelists discuss the treatment of CRPC, focusing on metastatic disease.
In the fifth segment of our roundtable series, the treatment of patients with CRPC is discussed.
In the fourth part of our series, the panelists discuss PROs and potential patient comorbidities.
In the third part of this series, disparities and the optimization of care is discussed, along with the use of ADT and ARPIs.
In the second segment of our roundtable series, the panelists discuss their approaches to the use of PSMA PET for patients.
In the first part of this series, the panel discusses treatments in the post-salvage setting and review therapeutic options.
At ESMO Congress 2024, Drs. Petros Grivas, Bernadett Szabados, and Karine Tawagi discuss ctDNA biomarkers.
Dr. Oliver Sartor gives an overview of the SPLASH trial on PSMA-targeted therapies for patients with prostate cancer.
Dr. Sonpavde analyzes the efficacy of the SMARCA2 degrader, nivolumab plus gemcitabine and cisplatin, and more.
Dr. Guru Sonpavde discusses urothelial carcinoma trials AMBASSADOR, NIAGARA, CM901, and PRT3789.
Dr. Gerhardt Attard discusses the benefits of the Decipher score as utilized during the STAMPEDE trial.
The Decipher score demonstrated a notable benefit in predicting patient survival rates during the STAMPEDE trial.
Dr. Gerhardt Attard provides insight on the STAMPEDE study, along with the Decipher score used during the trial.
Experts at ESMO Congress 2024 discuss novel therapies for castration-resistant prostate cancer.
Experts review the CONTACT-02 trial as well as the Decipher score utilized in the STAMPEDE trial.
The roundtable of experts discuss the realities of the SPLASH trial's hazard ratio and overall survival results.
At ESMO 2024, experts discuss androgen-deprivation therapy in HSPC as well as the ARANOTE trial.
Experts at ESMO 2024 discuss the implications and insights associated with the Peace III trial.
Experts discuss mHSPC discuss risk stratification, developed novel approaches for treatment, and treatment sequencing.
Dr. Drakaki highlights the VOLGA study and its practice-changing potential for patients with muscle-invasive bladder cancer.
Drs. Samantha Armstrong and Karine Tawagi provide updated commentary on STAMPEDE, SunRISe-4, and SUNNIFORECAST trials.
Dr. Armstrong reviews a handful of GU studies presented, including NIAGRA and STAMPEDE.
Dr. Koshkin highlights phase 2 data on futibatinib plus pembrolizumab for advanced urothelial carcinoma.
Drs. Tawagi and Wallis review the PEACE-III, STAMPEDE, UpFrontPSMA, and SPLASH studies trials at the ESMO Congress 2024.
Drs. Karine Tawagi and Christopher Wallis review the SUNNIFORECAST and TiNivo-2 trials at the ESMO Congress 2024.
Drs. Karine Tawagi and Christopher Wallis review the SunRISe-1 and AMBASSADOR trials at the ESMO Congress 2024.
Drs. Tawagi, Nizam encourage earlier monitoring and intervention to mitigate EV-induced neuropathy in certain patients.
Dr. Grande discusses the importance of durvalumab for shifting the MIBC treatment landscape.
Dr. Jensen highlights the single-arm trial design and TOMBOLA's use of ctDNA.
Dr. Hussain provides his thoughts on how and why to increase worldwide attention on rare forms of bladder cancer.
Dr. Hussain summarizes his presentation on rare and predominant variant histologies in bladder cancer.
Dr. Galsky discusses the value of HER2 status and the promising 75% ORR from the phase 2 trial.
Additional evidence for neoadjuvant therapy for patients undergoing RC, ineligible for neoadjuvant platinum-based chemo.
SPLASH continues to show benefit for PSMA RLT in mCRPC and adds to this consideration in the pre-chemotherapy setting.
The TiNivo-2 trial found that a tivozanib-nivolumab combination therapy did not improve outcomes over tivozanib alone.
The final results of the CONTACT-02 trial show favorable, but not statistically significant, benefit for cabo/atezo in mCRPC.
Perioperative durvalumab with NAC offers “meaningful improvement” in EFS and OS for patients with cisplatin-ineligible ...
Results of SunRISe-1 provide support for TAR-200 monotherapy in patients with BCG-unresponsive high-risk NMIBC.
The combination of ipilimumab/nivolumab may be a new standard in some subgroups of patients with metastatic nccRCC.
Drs. Necchi, Tawagi discuss the interim analysis of SunRISe-4 - TAR-200 plus cetrelimab or cetrelimab alone in MIBC patients.
Drs. Necchi and Tawagi highlight some the challenges in penile cancer, including "suboptimal" neoadjuvant, adjuvant options.
Dr. Pobel offers an overview of the ancillary study of the PEACE-1 trial, including how immunohistochemistry was used.
Drs. Barata and Tawagi provide updates in nccRCC, including SAMETA, PAPMET2, SUNNIFORECAST, and updated NCCN guidelines.
ctDNA testing may help identify patients with bladder cancer who would benefit from early post-cystectomy immunotherapy.
EV/pembro may offer first-line PFS and OS benefit in patients with la/mUC, regardless of Nectin-4 expression.
A phase 2 study highlights the “encouraging” antitumor activity from futibatinib plus pembrolizumab for patients with ...
Disitamab vedotin plus pembrolizumab shows promising efficacy, manageable safety in HER2+ aUC, with a 61.1% response rate.
Prognostic and predictive phenotypic biomarkers have been identified for rPFS and OS in de novo mCSPC.
The addition of nivo to trimodality therapy may improve RFS in patients with non-metastatic muscle-invasive bladder cancer.
PFS was improved with nivolumab plus cabozantinib.
Advertisement
GU Oncology Now delivers the latest news in clinical trials, conference coverage, and more, highlighting advancements in genitourinary oncology treatments and tech.
Get conference updates straight to your inbox.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.